Abstract
A study of RUSH specific immunotherapy by sublingual route has been performed. Twenty patients have been studied suffering from rhinoconjunctivitis a/o allergic asthma to grass pollen, divided in two homogeneous groups. The first group was treated with immunotherapy, the other was used as a comparison in open. The level of specific IgG4, specific IgE, drug consumption and the symptom score were monitored. The symptom and drug scores recorded by the patients during the pollen season were significantly reduced in the group undergoing sublingual allergen administration, thus proving the clinical efficacy of this treatment. There has not been, however, a significant reduction of specific IgE, nor a significant increase of specific IgG4 towards grasses, in the treated group, monitored before and at the end of the immunotherapy.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Absorption
-
Administration, Sublingual
-
Adult
-
Albuterol / therapeutic use
-
Allergens / administration & dosage
-
Allergens / therapeutic use*
-
Asthma / drug therapy
-
Asthma / immunology
-
Asthma / therapy*
-
Beclomethasone / therapeutic use
-
Conjunctivitis, Allergic / drug therapy
-
Conjunctivitis, Allergic / immunology
-
Conjunctivitis, Allergic / therapy*
-
Desensitization, Immunologic / methods*
-
Female
-
Humans
-
Immunoglobulin E / blood
-
Immunoglobulin G / blood
-
Male
-
Mouth Mucosa / metabolism
-
Pilot Projects
-
Poaceae / immunology
-
Pollen / immunology*
-
Rhinitis, Allergic, Seasonal / drug therapy
-
Rhinitis, Allergic, Seasonal / immunology
-
Rhinitis, Allergic, Seasonal / therapy*
-
Seasons
-
Terfenadine / therapeutic use
-
Time Factors
-
Treatment Outcome
Substances
-
Allergens
-
Immunoglobulin G
-
Immunoglobulin E
-
Terfenadine
-
Beclomethasone
-
Albuterol